secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALNYLAM PHARMACEUTICALS, INC. (ALNY)
CIK:        0001178670
Form:       8-K
Filed at:   2026-02-12T23:59:59+00:00
Accession:  0001628280-26-007491
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alnylam posts Q4 net product rev $995M (+121%); achieves full-year GAAP profitability
--------------------------------------------------------------------------------

- Q4 2025 net product revenue $995M (+121% YoY); full-year $2,987M (+81%); total revenue Q4 $1.1B.
- GAAP net income $111.5M ($0.82 diluted EPS) vs. loss a year ago; full-year GAAP net income $313.7M.
- Non-GAAP operating income $849.8M for FY2025; company expects sustainable operating income growth.
- AMVUTTRA (ATTR-CM) drove TTR franchise: Q4 $827M, full year $2,314M (+103% YoY).
- Launches 'Alnylam 2030' strategy; plans $250M manufacturing expansion; board appoints Stuart Arbuckle.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1178670/000162828026007491/0001628280-26-007491-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1178670/000162828026007491/alny-20260212.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-007491

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer